**Supplemental Digital Content 3:** Therapies prior to rituximab

|  |  |
| --- | --- |
|  | **N (%)** |
| **Biological DMARDS** | **92 (80.7%)** |
| * TNF inhibitors
 | 87 (76.3%) |
| * abatacept
 | 5 (4.4%) |
| * tocilizumab
 | 4 (3.5%) |
| **Reason for discontinuation** |  |
| lack of effectiveness | 88 (77.5%) |
| adverse reaction | 17 (14.8%) |
| other reason | 8 (7.7%) |
| **Non biological DMARDS** | **102 (89.5%)** |
| * methotrexate
 | 55 (48.3%) |
| * leflunomide
 | 59 (51.8%) |
| * hydroxychloroquine
 | 41 (36.0%) |
| * sulfasalazine
 | 35 (30.7%) |
| * cyclosporin
 | 14 (12.3%) |
| * azathioprine
 | 4 (3.5%) |

Abbreviations: DMARDS: disease-modifying anti-rheumatic drugs.